NCT01319864 - POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

June 28, 2013

Study Completion Date

June 28, 2016

Conditions

Relapsed/Refractory AMLRelapsed/Refractory ALLSecondary AML/MDSAcute Leukemia of Ambiguous LineageAMLALL

Interventions

DRUG

Plerixafor Dose Escalation

"Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy."

Trial Locations (9)

10021

Memorial Sloan-Kettering Cancer Center, New York

17033

Penn State Hershey Children's Hospital, Hershey

21231

Johns Hopkins Medical Center, Baltimore

30322

Children's Healthcare of Atlanta/Emory University, Atlanta

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

64108

The Children's Mercy Hospital and Clinics, Kansas City

80045

The Children's Hospital of Denver, Denver

85016

Phoenix Children's Hospital, Phoenix

T3B 6A8

Alberta Children's Hospital, Calgary